HIMS vs NVO: which stock is the better buy?
Hims & Hers Health Inc and Novo Nordisk A/S, graded by the same fixed-weight model from live fundamentals — composite score, 12-month forecast, valuation, growth and margins, side by side. As of September 14, 2026.
On today’s numbers, Novo Nordisk A/S grades higher — 62/100 vs 51/100. Tap either card for the full factor breakdown.
Metric by metric
| Metric | HIMS | NVO |
|---|---|---|
| TradersQuant Score | 51/100 | 62/100 ✓ |
| Price | $27.51 | $43.07 |
| 12-mo base forecast | $23.61 | $43.06 |
| Implied upside | -14.2% | -0.0% ✓ |
| Bull / bear range | $37.40 / $13.32 | $60.99 / $31.35 |
| P/E | — | 10.9 |
| Forward P/E | — | 14.4 |
| Revenue growth (YoY) | +28.0% ✓ | +5.6% |
| Gross margin | 69.5% | 80.7% ✓ |
| Market cap | $6.4B | $1.27T |
| Sector | Health Care | Pharmaceuticals |
✓ marks the stronger reading per metric (lower is better for P/E). Figures refresh continuously; research, not financial advice.
Want the full verdict on HIMS and NVO?
The AI bull/base/bear thesis, smart-money positioning, options signals and insider activity on both — every systematic call graded in public against the S&P 500.
$0 today · cancel before day 7 and you won’t be charged
HIMS vs NVO — FAQ (2026)
Is HIMS or NVO the better buy right now?
On the live TradersQuant composite score, Novo Nordisk A/S (NVO) currently grades higher at 62/100 versus 51/100 for HIMS. The score weighs valuation, growth, earnings quality, momentum, the macro regime, sentiment and balance-sheet risk — open each stock's page for the full breakdown. Research, not financial advice.
Which has more 12-month upside, HIMS or NVO?
TradersQuant's 12-month base-case forecast currently implies -14.2% for HIMS and -0.0% for NVO. Both forecasts are three-scenario models (bull/base/bear) refreshed continuously and graded on our public track record.
How is this HIMS vs NVO comparison calculated?
Both stocks are scored by the same fixed-weight model — 20% valuation, 20% growth, 15% earnings quality, 15% momentum, 10% macro regime fit, 10% analyst sentiment, 10% balance-sheet risk — from live fundamentals and prices. No hand-picking: the same arithmetic runs on every stock we cover, and our systematic calls are graded in public against the S&P 500.